Complete responders to checkpoint inhibitors in advanced melanoma: Relapse risk factors, and patients' outcomes.

9550Background: Since the development of immune checkpoint inhibitors (ICI) for advanced melanoma, a small group of patients with an excellent and durable response has emerged. Complete response (C...